Analysis Cervical + Radiotherapy + Chemotherapy

Authors: Heijkoop ST, Franckena M, Thomeer MG, Boere IA, Van Montfort C, Van Doorn HC.
Publication: Int J Hyperthermia. 2012;28(6):554-61. doi: 10.3109/02656736.2012.674622. Epub 2012 Jun 12.

OBJECTIVE:
To evaluate the efficacy of neoadjuvant chemotherapy, followed by radiotherapy and concurrent hyperthermia (triple therapy) in patients with advanced-stage cervical cancer.

Analysis Phase III Rectal + Radiotherapy + Chemotherapy

Authors: Schroeder C, Gani C, Lamprecht U, von Weyhern CH, Weinmann M, Bamberg M, Berger B.
Publication: Int J Hyperthermia. 2012;28(8):707-14. doi: 10.3109/02656736.2012.722263. Epub 2012 Sep 24.

PURPOSE:
To evaluate the influence of regional hyperthermia on rates of complete pathological response (pCR) and sphincter-sparing surgery in the context of an up-to-date radiochemotherapy protocol for locally advanced rectal cancer.

Phase I/II Ovarian + Chemotherapy

Authors: Alvarez Secord A, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW.
Publication: Int J Hyperthermia. 2005 Jun;21(4):333-47.

OBJECTIVE:
A phase I/II study of Doxil combined with whole abdomen hyperthermia was conducted in patients with refractory ovarian cancer. Liposomal doxorubicin combined with hyperthermia has been shown to increase both liposomal delivery and drug extravasation into tumour xenografts resulting in enhanced cytotoxic effects.

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: M Romano, S Maluta, C Cordiano, G.G Delaini, M Genna, C Oliani, P Capelli, A Tomezzolli, C Manfrini, A.B Porcaro, M Gabbani, G Chierego
Publication: International Journal of Radiation Oncology, October 1, 2003Volume 57, Issue 2, Supplement, Pages S386–S387

PURPOSE:
To evaluate toxicity and pathological complete response rate in treating preoperatively rectal cancer patients by radiation dose escalation combined with RH + CT.

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: Rau B, Wust P, Hohenberger P, Löffel J, Hünerbein M, Below C, Gellermann J, Speidel A, Vogl T, Riess H, Felix R, Schlag PM.
Publication: Ann Surg. 1998 Mar;227(3):380-9. Review.

OBJECTIVE:
A prospective phase II study was performed to determine the feasibility and efficacy in terms of response rate, resectability, and morbidity in patients with locally advanced rectal cancer who received preoperative regional hyperthermia combined with radiochemotherapy (HRCT).

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: Rau B, Wust P, Tilly W, Gellermann J, Harder C, Riess H, Budach V, Felix R, Schlag PM.
Publication: Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):381-91.

PURPOSE:
Preoperative radiochemotherapy (RCT) is a widely used means of treatment for patients suffering from primary, locally advanced, or recurrent rectal cancer. We evaluated the efficacy of treatment due to additional application of regional hyperthermia (HRCT) to this conventional therapy regime in a Phase II study, employing the annular phased-array system BSD-2000 (SIGMA-60 applicator). The clinical results of the trial were encouraging. We investigated the relationship between a variety of thermal and clinical parameters in order to assess the adequacy of thermometry, the effectiveness of hyperthermia therapy, and its potential contribution to clinical endpoints.

Phase I/II Ovarian + Chemotherapy

Authors: Hahn CA, Jones EL, Blivin JL, Sanders LL, Yu D, Dewhirst MW, Secord AA, Prosnitz LR.
Publication: Int J Hyperthermia. 2005 Jun;21(4):349-57.

PURPOSE:
Prospective assessment of quality of life (QoL) in patients with refractory, residual or recurrent ovarian cancer receiving whole abdomen hyperthermia and intravenous liposomal doxorubicin chemotherapy.

Phase II Bladder + Radiotherapy + Chemotherapy

Authors: Wittlinger M, Rödel CM, Weiss C, Krause SF, Kühn R, Fietkau R, Sauer R, Ott OJ.
Publication: Radiother Oncol. 2009 Nov;93(2):358-63. doi: 10.1016/j.radonc.2009.09.018.

PURPOSE:
To assess the safety and effectiveness of treating high-risk T1 and T2 bladder cancer with transurethral resection (TUR-BT) followed by radiochemotherapy (RCT) combined with regional deep hyperthermia (RHT).

Phase II Cervical + Radiotherapy + Chemotherapy

Authors: Sreenivasa G, Hildebrandt B, Kümmel S, Jungnickel K, Cho CH, Tilly W, Böhmer D, Budach V, Felix R, Wust P.
Publication: Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1159-67. Epub 2006 Sep 18.

PURPOSE:
To evaluate preoperative radiochemotherapy combined with regional pelvic hyperthermia in patients with nonresectable cervical cancer >/= International Federation of Gynecology and Obstetrics (FIGO) IIB "bulky" in a Phase II study.

Phase II Rectal + Radiohemotherapy

Authors: Milani V, Pazos M, Issels RD, Buecklein V, Rahman S, Tschoep K, Schaffer P, Wilkowski R, Duehmke E, Schaffer M.
Publication: Strahlenther Onkol. 2008 Mar;184(3):163-8. doi: 10.1007/s00066-008-1731-8.

PURPOSE:
Encouraging results of phase II studies combining chemotherapy with radiotherapy have been published. In this study, the results of a multimodal salvage therapy including radiochemotherapy (RCT) and regional hyperthermia (RHT) in preirradiated patients with recurrent rectal cancer are reported.

Phase I/II Ovarian + Chemotherapy

Authors: Fotopoulou C, Cho CH, Kraetschell R, Gellermann J, Wust P, Lichtenegger W, Sehouli J.
Publication: Int J Hyperthermia. 2010;26(2):118-26. doi: 10.3109/02656730903369200.

PURPOSE:
Due to the poor prognosis of patients with ovarian cancer relapse (OCR), newer strategies are warranted to improve the therapeutic index. We performed a prospective phase I/II-study of regional abdominal hyperthermia (RHT) combined with systemic chemotherapy in OCR patients in order to evaluate outcome, efficacy and tolerance.

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: Maluta S, Romano M, Dall'oglio S, Genna M, Oliani C, Pioli F, Gabbani M, Marciai N, Palazzi M.
Publication: Int J Hyperthermia. 2010;26(2):108-17. doi: 10.3109/02656730903333958.

PURPOSE:
To evaluate the safety of delivering pre-operative regional hyperthermia (HT) plus an intensified chemo-radiotherapy (CRT) regimen in patients suffering from locally advanced rectal cancer.

Open Label Pancreatic + Radiotherapy + Chemotherapy

Authors: Maluta S, Schaffer M, Pioli F, Dall'oglio S, Pasetto S, Schaffer PM, Weber B, Giri MG.
Publication: Strahlenther Onkol. 2011 Oct;187(10):619-25. doi: 10.1007/s00066-011-2226-6. Epub 2011 Sep 19.

PURPOSE:
To evaluate the therapeutic effect of delivering regional hyperthermia (HT) plus chemoradiotherapy (CRT) in patients suffering from locally advanced unresectable pancreatic cancer (LAPC).

Phase II Genitourinary + Chemotherapy

Authors: Petrovich Z, Emami B, Kapp D, Sapozink MD, Langholz B, Oleson J, Lieskovsky G, Astrahan M.
Publication:Am J Clin Oncol. 1991 Dec;14(6):472-7.

PURPOSE:
During a 6-year period, 53 patients with advanced tumors of the genitourinary tract were treated in Phase I protocols with deep regional hyperthermia in combination with irradiation (83%) or in combination with chemotherapy (11%).

Phase II Rectal + Chemotherapy

Authors: Hildebrandt B, Wust P, Dräger J, Lüdemann L, Sreenivasa G, Tullius SG, Amthauer H, Neuhaus P, Felix R, Riess H.
Publication: Int J Hyperthermia. 2004 Jun;20(4):359-69.

PURPOSE:
The aim of this study was to evaluate the feasibility and toxicity of a novel hyperthermic chemotherapy approach for patients with locally recurrent adenocarcinoma of the rectum. All patients were pre-irradiated (> or = 45 Gy) and had histologically proven pelvic recurrence.

Phase II Soft Tissue Sarcoma + Radiotherapy + Chemotherapy

Authors: Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, Hiddemann W, Issels RD.
Publication:J Clin Oncol. 2002 Jul 15;20(14):3156-64.

PURPOSE:
From 1991 to 1997, 58 patients with HR-STS at RP/V sites were prospectively treated with four cycles of etoposide, ifosfamide, and doxorubicin combined with RHT followed by surgery, adjuvant chemotherapy, and radiation.

Phase II Deep Tumor + Radiotherapy + Chemotherapy

Authors: Tilly W, Wust P, Rau B, Harder C, Gellermann J, Schlag P, Budach V, Felix R.
Publication: Int J Hyperthermia. 2001 Mar-Apr;17(2):172-88.

PURPOSE:
The system BSD 2000 has been in clinical use for regional hyperthermia for more than 10 years. Several technical details of this hyperthermia system, as well as the results of clinical studies employing this system have been investigated. The intention of this paper is to investigate the correlation between technical efficiency or feasibility of hyperthermia with the BSD 2000, in terms of power densities and temperatures depending upon parameters such as tumour histology, tumour location, patient age, patient sex, and patient cross section.

Phase II Soft Tissue Sarcoma + Radiotherapy + Chemotherapy

Authors: Schlemmer M, Wendtner CM, Lindner L, Abdel-Rahman S, Hiddemann W, Issels RD.
Publication: Int J Hyperthermia. 2010;26(2):127-35. doi: 10.3109/02656730903335995.

PURPOSE:

We report data from phase II trials examining the efficacy of multimodality treatment with neoadjuvant chemotherapy, hyperthermia, surgery, radiation and postoperative thermochemotherapy in adult patients with high-risk sarcomas of the extremities.

Phase II Soft Tissue Sarcoma + Chemotherapy

Authors:  Wendtner C, Abdel-Rahman S, Baumert J, Falk MH, Krych M, Santl M, Hiddemann W, Issels RD
Publication: Eur J Cancer. 2001 Sep;37(13):1609-16.

PURPOSE:
The efficacy of thermochemotherapy in adult patients with primary, recurrent or inadequately resected non-metastatic high-risk soft-tissue sarcomas (STS) was assessed.

Phase I Germ cell + Chemotherapy

Authors: Schneider DT, Wessalowski R, Calaminus G, Pape H, Bamberg M, Engert J, Waag K, Gadner H, Göbel U.
Publication: J Clin Oncol. 2001 Apr 1;19(7):1951-60.

PURPOSE:

To evaluate therapeutic options for recurrent malignant sacrococcygeal germ cell tumors (GCT) following three-agent, cisplatinum-based, first-line chemotherapy and tumor resection.